Market Overview

What Maxim Thinks Of Cytori After Its Huge Week


In a report published Wednesday, Maxim Group analyst Jason Kolbert discussed Cytori Therapeutics Inc (NASDAQ: CYTX)'s announcement earlier this week that the European Medicines Agency Committee for Orphan Medicinal Products has designed Cytori's ECC S-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma.

Kolbert noted that the regulatory clearance officially makes Cytori's Celution System available in the largest healthcare market in the world and triggers a "substantial" 2015 product purchase order for Cytori from Lorem Vascular Pte. Ltd.

Related Link: Exclusive: Cytori Therapeutics CEO Talks About Two Major Announcements In Two Days

Meanwhile, Cytori is about to begin a phase 3 clinical trial in the U.S. with the same product in up to 20 sites. Kolbert stated that the clinical data could also be used to support regulatory approvals and reimbursement in the European Union as well as other global markets.

Shares remain Buy rated with a $7 price target.

Posted-In: ECC S-50 European Medicines Agency Committee for Orphan Medicinal Products Jason Kolbert Lorem VascularAnalyst Color Health Care Analyst Ratings General


Related Articles (CYTX)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

How's Apple Doing In China?

These Analysts Love FedEx's TNT Express Acquisition